人免疫重建荷人HPV16阳性宫颈癌SCID鼠模型的建立及其生物学特征研究

目的 :建立人免疫重建荷人HPV16阳性宫颈癌 -严重联合免疫缺陷小鼠模型并研究其生物学特征。方法 :向严重联合免疫缺陷 (SCID)鼠腹腔注射人外周血淋巴细胞 (PBL)后 2 4h ,皮下接种HPV16阳性的人宫颈癌细胞株SiHa细胞建立人免疫重建荷人HPV16阳性宫颈癌SCID鼠模型 ,观察荷瘤鼠成瘤、一般特征和移植瘤生长、转移情况及组织学特征 ,检测外周血、肿瘤组织和肺脾等其它组织中HPV16DNA、血清中人IgG含量和移植物抗宿主情况。结果 :SCID小鼠成瘤率为 10 0 % ,移植瘤生长以局部浸润为主 ,未见转移瘤。免疫重建荷瘤组生存期 (136 .2± 6 .3d)显著长于未重建荷瘤组 (97.8± 3.7d) ;组织学检查示移植前后肿瘤细胞形态相似 ;所有肿瘤组织中HPV16DNA呈阳性 ,而外周血和肺脾等其它组织均为阴性。未发现移植物抗宿主情况。结论 :成功建立的人免疫重建荷人HPV16阳性宫颈癌SCID小鼠模型能较好地模拟人自发宫颈癌的生物学特征     

白细胞介素24对裸鼠人宫颈癌Hela细胞移植瘤抑制作用的探讨

目的：探讨基因重组质粒pDC316-hIL-24对裸鼠人宫颈癌模型的肿瘤生长及凋亡的作用。方法：于5周龄裸鼠腋窝外侧皮下注射1×10 7个／mLHela细胞悬液100uL,将15只构建成功的人宫颈癌Hela细胞裸鼠模型随机分为3组,分别于瘤体内注射转染试剂Lipofectamine2000与基因重组质粒pDC316-hIL-24（A组）、空质粒pDC316（B组）以及磷酸盐缓冲液（C组）,比较干预后各组移植瘤的体积及抑瘤率。应用RT-PCR法测定移植瘤中h／L-24的表达．HE染色观察各组肿瘤组织形态学变化。免疫组化方法研究肿瘤细胞凋亡情况。结果：①IL-24基因成功转染人肿瘤细胞并在其中成功表达,至实验结束时,B组和C组移植瘤体积大于A组（F=63．395,P〈0．05）;A组的平均抑瘤率高于B组（t=130．920,P〈0．01）。②病理学观察见A组宫颈癌细胞有局灶性坏死,细胞变大,胞质疏松,核深染,可见核固缩、核溶解、核碎裂,染色质成团状。⑧免疫组化结果显示,A组BCL-2蛋白表达低于其他2组（F=6．164,P〈0．05）,而其同源蛋白BAX表达高于其他2组（F=58．426,P〈0．05）。结论：基因重组质粒pDC316-hIL-24对宫颈癌裸鼠模型肿瘤生长具有明显的抑制作用,其可能通过激活细胞凋亡通路而诱导肿瘤细胞凋亡。     

PinlsiRNA对宫颈癌细胞SiHa增殖和凋亡的影响

目的：通过小干扰RNA（siRNA）栽体介导抑制肽基脯氨酰同分异构酶（Pinl）表达,探讨Pinl对宫颈癌细胞SiHa增殖与凋亡的影响。方法：构建pGPU6／GFP／Neo—PinlsiRNA表达载体,脂质体介导将其转染至宫颈癌细胞SiHa中;实验设3组：实验组（SiHa／pGPU6-PinlsiRNA组）、阴性对照组（SiHa／pGPU6-con组）和空白对照组（Si-Ha）。采用RT—PCR、Western blot法检测Pinl的表达;M1Tr法检测细胞增殖活性;原位末端标记法（TUNEL）和流式细胞术（FCM）检测细胞凋亡。结果：转染SiHa／pGPU6．PinlsiRNA的SiHa细胞中,PinlmRNA和蛋白表达分别下调68．1％和54．8％,细胞增殖显著抑制。TUNEL显示典型细胞凋亡特征,SiHa／pGPU6-PinlsiRNA组的凋亡指数（AI）为（29．6±14．58）％,显著高于SiHa／pGPU6-con组[（8．44±5．65）％]和空白对照组[（5．34±4．47）％]（P〈O．05）。SiHa／pGPU6．PinlsiRNA组的细胞凋亡率为（30．95±16．47）％,显著高于SiHa／pGPU6-COIl组[（6．18±6．10）％]和空白对照组[（5．95±4．99）％]（P〈0．05）。结论：RNA干扰技术能特异高效的抑制Pinl基因的表达,Pinl基因的下调能抑制宫颈癌细胞增殖并促进细胞凋亡,提示Pinl可能成为治疗宫颈癌的新靶点。     

细胞周期蛋白依赖性蛋白激酶抑制剂flavopiridol对卵巢上皮性癌细胞及移植瘤干预作用

目的检测细胞周期蛋白依赖性蛋白激酶抑制剂flavopiridol对卵巢上皮性癌（卵巢癌）细胞及移植瘤的干预作用。方法应用流式细胞仪和脱氧核苷酸末端转移酶介导的脱氧尿苷三磷酸标记法（TUNEL）检测flavopiridol作用后卵巢癌细胞系AO的细胞凋亡率和细胞周期,应用实时荧光定量PCR技术检测flavopiridol作用前、后AO细胞中细胞周期蛋白（cyclin）D和活性半胱氨酸天冬氨酸蛋白酶（caspase）3的表达情况。建立卵巢癌裸鼠皮下及腹腔移植瘤模型,观测flavopiridol干预后裸鼠的生存情况及肿瘤体积的变化,TUNEL和免疫组化方法分别检测肿瘤组织中的细胞凋亡情况和微血管密度（MVD）。结果AO细胞在150、300、500nmol／L浓度的flavopiridol作用下,凋亡率分别为4．1％、10．7％和7．6％;G1期细胞比例显著增加,S期比例显著降低（P〈0．05）。flavopiridol作用后AO细胞cyclin D的表达量（0．25）显著下降,活性caspase-3的表达量（2．55）轻度升高,高于flavopiridol作用前的0．69（P〈0．05）、2．49（P〉0．05）。flavopiridol干预后裸鼠的累积生存率显著提高（P〈0．05）;裸鼠的平均生存时间为（141±14）d,显著高于磷酸盐缓冲液（PBS）作用后的（106±11）d,两者比较,差异有统计学意义（P〈0.05）;在flavopiridol干预后53d时抑瘤率为40％。flavopiridol干预后裸鼠的肿瘤组织中有细胞凋亡发生,MVD为（12±5）个,显著高于PBS作用后的（35±10）个,两者比较,差异有统计学意义（P〈0．05）。结论flavopiridol能显著抑制卵巢癌细胞及移植瘤的生长,延长荷瘤裸鼠的生存期。     

乳源免疫调节肽抗人卵巢癌的实验研究

目的:通过荷人卵巢癌裸鼠模型,研究乳源免疫调节肽(PGPIPN)的抑癌作用.方法:建立荷人卵巢癌裸鼠模型,皮下接种肿瘤细胞后,分别用0.9%氯化钠液(NS组),低剂量PGPIPN(2.5×10-4 mg/L)(PGPIPN1组),高剂量PGPIPN(5.0×10-4mg/L)(PGPIPN2组),0.2 ml隔日腹腔注射;氟尿嘧啶(5-Fu)(30 mg/kg·d)(5-Fu组)通过腹腔注射.种植5周后处死裸鼠,测量荷人卵巢癌裸鼠的体重、瘤重、脾重,计算抑瘤率、脾指数,观察PGPIPN对卵巢癌肿瘤的抑制作用,并通过HE染色、DNA凝胶电泳分析技术观察PGPIPN对卵巢癌细胞及其DNA的影响.结果:荷人卵巢癌裸鼠经PGPIPN治疗后出现肿瘤体积缩小,PGPIPN2组抗瘤效果优于PGPIPN1组,同时还能改善荷人卵巢癌裸鼠的体质,提高荷人卵巢癌裸鼠的生存质量,增强SKOV3裸鼠免疫功能.组织病理学检查发现:PG-PIPN1组可见小片状瘤细胞发生凋亡,PGPIPN2组可见瘤细胞大片发生凋亡.PGPIPN组的瘤组织中提取的DNA进行琼脂糖电泳均出现特征性DNA梯形电泳条带.结论:PGPIPN有明显的抑瘤效应,可诱导人卵巢癌细胞发生凋亡.这为卵巢癌的治疗提供了新方法.     

IL-24对宫颈癌Hela细胞株增殖和凋亡的影响

目的探讨抑癌基因IL-24对宫颈癌Hela细胞株增殖和凋亡的影响。方法将携带有目的基因IL-24的穿梭质粒pAd track CMV转染入体外培养的宫颈癌Hela细胞,用MTT法检测细胞的增殖情况,用流式细胞仪测定细胞周期及凋亡率。同时以转染空载体pAd track CMV的Hela细胞和野生型Hela细胞作为空载体对照和阴性对照。结果经MTT法测定,三组之间OD值总体上有差异（P〈0.001）,IL-24组OD值明显低于空质粒组和阴性对照组（P〈0.001）,而空质粒组和阴性对照组的OD值无明显差异（P=0.661）;经流式细胞仪测定,三组之间的细胞早期凋亡率总体上有差异（P〈0.05）,IL-24组细胞早期凋亡率明显高于空质粒组和阴性对照组（P〈0.05）,而空质粒组和阴性对照组的细胞早期凋亡率无明显差异（P〉0.05）;与空质粒组和阴性对照组相比,IL-24组G0/G1期细胞增多（P〈0.05）,S期细胞减少（P〈0.05）,而空质粒组和阴性对照组无明显差异（P〉0.05）。结论IL-24对宫颈癌Hela细胞有抑制增殖、诱导凋亡的作用。     

子宫颈癌组织中抑癌基因DNA甲基化的检测

目的 通过分析宫颈上皮内瘤变（CIN）和宫颈癌组织中p16、CDH1、RASSF1A和TIMP3基因DNA甲基化的变化情况,探讨其在宫颈癌发生中的意义。方法 用甲基化特异性聚合酶链反应技术（MSP）对CINI组（40份）、CINⅡ～Ⅲ（40份）、宫颈癌组（40份）病变组织中p16、CDH1、RASSF1A和TIMP3基因DNA甲基化程度进行检测。另取正常宫颈组织20份作为对照组。结果（1）对照组中p16、CDH1、RASSF1A和TIMP3基因的DNA甲基化阳性率均为0。（2）p16和CDH1基因的DNA甲基化阳性率,CIN11～m组（分别为22％、35％）明显高于CINI组（分别为2％、5％,P〈0．05）;RASSF1A和TIMP3基因的DNA甲基化阳性率,CINⅡ～Ⅲ组（分别为12％、15％）虽高于CINI组（均为2％）,但差异无统计学意义（P〉0．05）。（3）宫颈癌组p16（40％）、CDH1（58％）、RASSF1A（20％）和TIMP3（35％）基因的DNA甲基化阳性率虽均高于CINⅡ-Ⅲ组,但差异无统计学意义（P〉0．05）。（4）宫颈癌组p16、CDH1、RASSF1A和TIMP3基因的DNA甲基化阳性率均高于CINI组,差异有统计学意义（P〈0．05）。（5）上述基因的DNA甲基化的总阳性率（即任何一个基因出现甲基化即为阳性）,宫颈癌组（90％）明显高于CINⅡ～Ⅲ组（55％,P〈0．05）,且此两组均明显高于CINI组（8％,P〈0．05）。结论 随着从宫颈不典型增生向浸润癌的进展,p16、CDH1、RASSF1 A和,TIMP3基因的DNA甲基化阳性率明显升高,提示抑癌基因的DNA甲基化在宫颈癌发生、发展中起着一定作用,可能成为判断宫颈癌发生、发展的重要指标。     

宫颈癌中细胞凋亡指数与放射治疗临床效果关系的研究

目的:研究宫颈癌中细胞凋亡指数与放射治疗（放疗）临床效果的关系。方法:对35例宫颈癌患者分别于放疗前和放疗1周后[用肿瘤剂量（DT）900-1000cGy],取标本,采用原位DNA末端终止法和免疫组化法（IHCA）分别检测细胞凋亡指数（AI）和凋亡相关基因bcl-2/bax。结果:放疗前和放疗第1周后AI分别为1.21％±0.78％、29.8％±8.4％,差异有高度显著性（P<0.01）;AI与bcl-2/bax的表达及与患者的临床疗效密切相关,RT前基础细胞凋亡指数（BAI）≥1.21％的临床疗效明显高于BAI<1.21％者（P<0.01）。结论:AI和患者的临床疗效具有相关性,检测BAI可预测患者对RT的敏感性。     

胰岛素对子宫内膜癌细胞增殖和凋亡的影响

目的 探讨胰岛素对子宫内膜癌细胞系Ishikawa3-H-12细胞增殖、凋亡和细胞周期的影响。方法 应用免疫细胞化学方法和RT-PCR技术检测Ishikawa3-H-12细胞胰岛素受体（INSR）蛋白和mRNA的表达。以不同浓度胰岛素作用Ishikawa3-H-12细胞不同时间,采用四甲基偶氮唑蓝比色法、流式细胞仪检测细胞增殖、凋亡和细胞周期。结果 （1）Ishikawa3-H-12细胞INSR蛋白呈棕黄色阳性表达,并可见INSR基因的表达。（2）胰岛素以浓度和时间依赖的方式促进子宫内膜癌细胞增殖,1×10^-4mol／L胰岛素作用48h时促增殖作用最显著,增殖率为（340．2±15．9）％,与对照细胞（以胰岛素浓度为0作为对照,为100％）比较,差异有统计学意义（P〈0．05）。（3）胰岛素以浓度和时间依赖的方式使Ishikawa3-H-12细胞中G0／G1期细胞比例减少,S期细胞比例增加,1×10^-4mol／L胰岛素作用72h时最显著,G0／G1期细胞比例为（27．7±2．5）％,S期细胞为（55．2±1．4）％,分别与对照细胞[分别为（67．6±1．5）％、（15．7±1．0）％]比较,差异均有统计学意义（P〈0．05）;胰岛素对G2／M期细胞无影响（P〉0．05）。（4）随着胰岛素浓度的增加,Ishikawa3-H-12细胞凋亡率逐渐下降。1×10^-4mol／L胰岛素作用最显著,作用24、48、72、96h时的细胞凋亡率分别为（1．76±0．16）％、（1．70±0．15）％、（1．56±0．20）％、（1．31±0．24）％,分别与对照细[分别为（9．81±0．61）％、（9．93±1．44）％、（9．10±0．66）％、（10．30±1．20）％]比较,差异均有统计学意义（P〈0．05）。结论 胰岛素对子宫内膜癌Ishikawa3-H-12细胞具有促进增殖、抑制凋亡的作用。     

DahIS高血压大鼠卵巢细胞凋亡相关因素的实验研究

目的：探讨高血压时卵巢细胞凋亡的调控机制。方法：以日本引进DahIS高血压大鼠为研究对象，应用流式细胞仪、生化等技术，对DahIS高血压大鼠卵巢细胞凋亡与Bcl-2,iNOS及NO等相关因素进行研究。结果：（1）随高血压病情加重，卵巢细胞凋亡率逐渐上升，与之伴随Bcl-2表达率逐渐下降，iNOS表达率逐渐升高，实验组与对照组比较差别显，P＜0．05。（2）11周龄实验组血清NO含量较对照组降低，两比较差别显，P＜0．01；而随高血压病情加重，实验组NO含量逐渐增高，反而高于对照组，两组比较差异有统计学意义，P＜0．05。丙二醛（MDA）随高血压病情加重逐渐增高，实验组与对照组比较差别显，P＜0．05。结论：随血压升高，卵巢细胞凋亡加重与Bcl-2调控及iNOS、NO直接作用有关。     

Antiproliferative activity and toxicity of 2-methoxyestradiol in cervical cancer xenograft mice

2-methoxyestradiol (2-ME) is considered to be an effective anticancer compound for many types of tumors. We have previously demonstrated that 2-ME inhibits the growth of human cervical cancer HeLaS3 cells in vitro. In this study, we investigated the antitumoral effects of 2-ME on human cervical carcinoma in severe combined immune deficient (SCID) mice. The potential side effects of 2-ME on the SCID mice were also investigated. SCID mice were injected with HeLaS3 cells (3 x 10(6) to 4 x 10(6)/mouse) and a 15-day administration of 2-ME followed after a 1-week cell implantation. Tumor weight, volume, body weight, and blood chemistry were determined. Tumor tissues were examined with an antibody against the proliferative cell nuclear antigen and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining. Liver, spleen, kidney, heart, and lung were screened by pathologic examinations. 2-ME (75 mg/kg p.o.) inhibited growth of human cervical carcinoma by 34% (P < 0.05) as compared with control. Necrosis was found in both 2-ME-treated and untreated tumor tissues, but the necrotic area was larger in 2-ME-treated mice. A low expression of proliferative cell nuclear antigen and an increased number of apoptotic cells were found in 2-ME-treated tumor sections as compared to those in controls. No significant difference was detected in blood chemistry. In addition, the liver showed hyperplastic Kupffer cells, hydropic swelling of hepatocytes, and liquefactive necrosis. The spleen showed an increased number of megakaryocytes and apoptotic cells after 2-ME treatment. Thus, 2-ME has an antitumor effect on human cervical carcinoma, and it is toxic to liver and spleen in this mouse model.     

Recombinant adenovirus-p53 gene transfer and cell-specific growth suppression of human cervical cancer cells in vitro and in vivo

PURPOSE: We investigated the time-course expression patterns of p53 and E6 on cervical cancer cells to obtain a molecular level understanding of cell-dependent tumor growth suppression effects of recombinant adenovirus expressing p53 in vitro and in vivo. METHODS: Four human papillomavirus (HPV)-infected human cervical cancer cell lines (HPV 16-positive cells, CaSki and SiHa cells; and HPV 18-positive cells, HeLa and HeLaS3 cells) were used. Also, HPV negative C33A and HT3 cell line that has a mutation on p53 gene were used. After infection with AdCMVp53, the cell growth inhibition was studied via cell count assay, MTT assay, and Neutral red assay. After transfecting AdCMVp53 and AdCMVLacZ into the cancer cells-xenografted nude mice, antitumor effects were investigated for 1 month, respectively. RESULTS: For each cervical cancer cell, IC50 was as follows; CaSki (68.5 multiplicity of infection, or MOI), SiHa (43.5 MOI), HeLa (31 MOI), HeLaS3 (42 MOI), C33A (21 MOI), and HT3 (62 MOI). In particular, complete inhibition of cell growth was observed at 125 MOI in both CaSki and SiHa cells. However, the complete inhibition was detected at 62.5 MOI in HeLa and HeLaS3. In contrast, at these MOI, no suppression of cell growth was observed when cells were infected with recombinant adenovirus expressing beta-gal as a negative control. The levels of p53 protein were notably expressed in CaSki and HeLa more than in SiHa and HeLaS3 on days 2 and 4. However, the p53 was only detected in HeLaS3 on day 6. In contrast, p53 expression was continually maintained in C33A and HT3 during the same periods. After transfection AdCMVp53 into CaSki- and SiHa-xenografted nude mice, the size of tumor was remarkably decreased in SiHa cells as compared to AdCMVLacZ transfection. CONCLUSION: The adenovirus-mediated p53 gene transfection was done effectively in vitro and in vivo. Also, the antitumor effects were accomplished via differential role of p53-specific apoptotic cell death, which is dependent upon the cervical cancer cell line.     

Development of anticancer gene vaccine interact with human papillomavirus oncoprotein inhibition

Adeno-associated virus (AAV) Rep 78 protein is known to inhibit the promoter site of several oncogenes and viral genes, including the human papillomavirus (HPV) type 16 E6 transforming genes. The biochemical studies of Rep 78 have been reported, but the effects of Rep 78 gene-mediated inhibition of HPV 16 E6 promoter activity on the various human cervical carcinoma cells have not been characterized. pEGFP-N1 vector, cloned by AAV-mediated Rep 78, is transfected into cervical carcinoma cells. Transfection efficiency of Rep 78 was approximately 30-60% different. Messenger RNA (mRNA) and protein expression of Rep 78 gene was significantly higher on day 1 of the transfection of Rep 78 DNA in CaSki cells, and DNA level of HPV 16 E6 was decreased on day 1 of the transfection. The growth of CaSki cervical cancer cells was only 10-15% inhibited by Rep 78, and the other cervical cells, HeLa, HeLaS3, HT3, and QGU, were unaffected by Rep 78 transfection. In spite of the high efficiency of Rep 78 gene transformation and expression rate, we could not show the significant growth inhibition in various cervical cancer cell lines. Taken together, long-term expression of Rep 78 strategy might be needed for cervical carcinoma gene therapy using AAV vector.     

格尔德霉素对宫颈癌HeLa细胞中bcl-2表达的影响

目的:观察格尔德霉素(geldanamycin,GA)在体外对宫颈癌HeLa细胞抗凋亡基因bcl-2和mRNA转录、蛋白表达水平的影响。方法:分别给予宫颈癌HeLa细胞0,0.02,0.2,2,10μmol/L浓度GA处理24h,用annexin V方法检测细胞凋亡,半定量PCR检测bcl-2、Hsp90 mRNA转录水平,用10μmol/L的GA处理HeLa细胞3、12、24、48h后,Western blot检测bcl-2、Hsp90蛋白表达水平的变化。结果:宫颈癌HeLa细胞经不同浓度的GA作用24h,细胞凋亡指数呈剂量依赖性增加,bcl-2 mRNA表达呈剂量依赖性降低,bcl-2蛋白表达水平呈时间依赖性降低,处理组与对照组之间的差异有统计学意义;但GA对Hsp90 mRNA和蛋白表达水平无明显影响。结论:GA可抑制宫颈癌HeLa细胞抗凋亡基因bcl-2的转录和表达,促进凋亡。     

NS-398对宫颈癌HeLa细胞的生长抑制及诱导凋亡作用的研究

目的研究环氧合酶-2(COX-2)选择性抑制剂NS-398对宫颈癌细胞的作用及其作用机制,探讨NS-398在宫颈癌治疗中的可能性。方法用不同浓度NS-398作用于人宫颈癌HeLa细胞,CCK-8法检测NS-398对HeLa细胞增殖的影响;流式细胞仪PI染色法检测细胞周期改变;AnnexinⅤ-FITC/PI双标法检测细胞早期凋亡。结果 NS-398对人宫颈癌HeLa细胞的增殖具有明显抑制作用。其抑制率随着药物浓度的增高而增加,随着药物作用时间的延长而显著增高。与对照组比较,NS-398处理组G1期细胞明显减少,而S期细胞明显增多,两组比较,差异有统计学意义(P0.05);NS-398作用24h后,在10μmol/L组的HeLa细胞凋亡率为5.60%;20μmol/L组凋亡率为12.89%,而40μmol/L组的凋亡率高达27.03%,对照组HeLa细胞无凋亡。结论 NS-398对宫颈癌细胞具有明显的抑制作用,且呈剂量和时间依赖性。其对宫颈癌细胞的作用可能与诱导癌细胞凋亡有关。     

顺铂增强TRAIL蛋白诱导Caski细胞凋亡机理研究

目的:观察顺铂对TRAIL蛋白诱导子宫颈癌Caski细胞株凋亡的调节作用,并探讨其作用机理。方法:传代培养宫颈癌Caski细胞,依照所加药物不同,将细胞分为TRAIL组、顺铂组、TRAIL+顺铂组、TRAIL序贯顺铂组、顺铂序贯TRAIL组以及空白对照组,分别于加药后不同时间应用:(1)倒置显微镜观察细胞的生长状态;(2)MTT法检测TRAIL蛋白与顺铂单用、联用以及序贯应用对Caski细胞的生长抑制率;(3)Caspase-8活性检测试剂盒检测不同用药方式对Caski细胞Caspase-8活力的影响;(4)流式细胞术检测Caski细胞TRAIL受体DR4,DR5,DcR1,DcR2的表达,以及1.0mg/L顺铂作用细胞24h后表达量的变化;(5)半定量RT-PCR分析顺铂作用细胞8h后4种受体mRNA水平的变化。结果:(1)TRAIL蛋白和顺铂对Caski细胞有不同程度的生长抑制作用;(2)100ng/mlTRAIL蛋白和1.0mg/L顺铂单用作用24h细胞生长抑制率分别为35.44%、50.26%,联合应用后增至89.66%,联合用药与单独用药差异有统计学意义(P<0.05);(3)顺铂序贯TRAIL蛋白生长抑制率79.88%,TRAIL蛋白序贯顺铂55.73%,两实验组的差异有统计学意义(P<0.01);(4)Caspase-8活力在顺铂序贯TRAIL组的表达最强,为单用TRAIL组的1.52倍;(5)Caski细胞4种TRAIL受体均有表达,但表达丰度不同,顺铂可以上调死亡受体的表达;(6)顺铂处理细胞8h后DR4,DR5mRNA表达水平明显升高,DR4为对照组的1.40倍,DR5为对照组的1.57倍,差异有统计学意义(P<0.05);(7)用顺铂处理前后DcR1,DcR2表达差异无统计学意义(P>0.05)。结论:Caski为TRAIL蛋白敏感细胞,顺铂通过上调死亡受体4、5表达、提高Caspase-8活性,增强TRAIL蛋白抑制子宫颈癌Caski细胞生长的作用;顺铂序贯TRAIL的配伍方式具有更强的诱导Caski细胞凋亡的作用。     

氯化镧对子宫颈癌HeLa细胞增殖和迁移能力的影响

目的 探讨氯化镧对宫颈癌HeLa细胞增殖和迁移能力的影响,为寻找新的有效治疗宫颈癌的药物提供实验依据.方法 宫颈癌细胞株HeLa细胞经培养、传代后分为两组,即实验组(加入5、50、100 μmol/L的氯化镧)和对照组(未加入氯化镧).倒置显微镜下观察两组细胞的生长情况,激光共聚焦显微镜观察两组细胞核的形态变化.采用四甲基偶氮唑蓝(MTF)比色法检测两组细胞的增殖情况,双染色流式细胞仪检测两组细胞的凋亡率,体外迁移实验检测两组细胞迁移能力的变化,逆转录(RT)-PCR技术检测两组细胞中增殖、抗凋亡和迁移相关基因细胞周期蛋白(cyclinD1)、锌指蛋白(A20)及基质金属蛋白酶9(MMP-9)mRNA的表达.结果 倒置显微镜下观察:实验组细胞随着氯化镧浓度的升高,细胞密度逐渐降低,细胞质内颗粒逐渐增多,颜色加深,细胞间隙增大,少量细胞变圆漂浮,脱落细胞也逐渐增多;而对照组细胞贴壁生长密集,形态清晰,胞质饱满,相邻细胞生长融合成片.激光共聚焦显微镜观察:实验组细胞核染色质浓聚边集,核体积变小,随着氯化镧浓度的升高,核染色质崩解,核膜破裂、核碎裂,直至细胞核完全碎裂;而对照组细胞核饱满,核膜完整.实验组细胞经不同浓度(5、50、100 μmol/L)的氯化镧作用后,细胞生长抑制率分别为24%、51%、78%,高于对照组(0),差异有统计学意义(P<0.05);细胞凋亡率分别为(4.91±0.39)%、(7.30±0.71)%、(13.48±0.92)%,高于对照组的(0.89±0.11)%,差异有统计学意义(P<0.01);穿膜细胞数分别为(22.2±4.3)、(12.0±3.2)、(7.8±2.6)个,低于对照组的(41.2±5.4)个,差异有统计学意义(P<0.01).实验组细胞中cyclinD1、A20及MMP-9 mRNA的表达强度随氯化镧浓度(5、50、100 μmol/L)的升高逐渐减弱.结论 氯化镧通过下调宫颈癌细胞中增殖、抗凋亡和迁移相关基因cyclinD1、A20及MMP-9 mRNA的表达,抑制宫颈癌细胞的增殖和迁移并诱导其凋亡.     

Retinoic acid and interferon-alpha effects on cell growth and differentiation in cervical carcinoma cell lines

OBJECTIVE: To investigate and compare the efficacy of all-trans retinoic acid (RA) and/or interferon-alpha (IFN-alpha) on premalignant and malignant models of cervical cancer. METHODS: Cell growth rate was examined after treatment for 4, 7, and 10 days with RA and/or IFN-alpha of human papillomavirus type 18 (HPV 18)-immortalized endo- and ectocervical cells, nontransformed serum-adapted cells, transformed cells, three adenocarcinoma, and three squamous cell carcinoma cell lines. The effect on epithelial differentiation by RA and IFN-alpha was examined in organotypic culture. Induction of apoptosis was examined by modified terminal transferase-mediated deoxyuridine triphosphate-biotin nick end-labeling (TUNEL) and DNA fragmentation. RESULTS: Cell growth rate was inhibited by RA, 84-96% in HPV 18-immortalized endocervical cells, SiHa, and ME180, 0% in OMC-4, and 18-62% in other cell lines; and by IFN-alpha about 75% in SiHa and ME180 and 14-40% in the other cell lines. Combining RA and IFN-alpha increased the antiproliferative effect in premalignant cell lines and some cancer cell lines except OMC-4, SiHa, and HT-3. In rafts, RA treatment reversed human endocervical cell metaplasia and HPV 18-immortalized endo- and ectocervical cell dysplastic epithelial differentiation. Interferon-alpha, not RA, treatment of HPV 18-immortalized endo- and ectocervical cells induced apoptosis. CONCLUSION: Cell growth inhibition by treatment with RA, IFN-alpha, and their combination differentially depends on treatment type and time, cell origin, cell line, and oncogenic state. In a premalignant model of cervical carcinoma, RA reduces dysplastic differentiation and IFN-alpha induces apoptosis. These data confirm that these treatments may be effective for preventing or treating premalignant cervical lesions.     

红景天苷对宫颈癌HeLa 细胞增殖抑制作用的研究

目的：探讨不同浓度红景天苷对宫颈癌HeLa细胞增殖的抑制作用及其作用机制。方法：浓度分别为5,50,500 μg/mL的红景天苷体外培养HeLa细胞24 h后,应用噻唑蓝（MTT）法观察红景天苷对HeLa 细胞的生长抑制作用,流式细胞技术及Hoechst核染色法观察各组HeLa细胞凋亡情况,比色法检测凋亡相关因子Caspses-3及Caspase-9的表达。结果：红景天苷能明显抑制HeLa细胞增殖,不同剂量（5,50,500 μg/mL）红景天苷组的细胞存活率[（82.00±3.65）%,（59.33±2.39）%,（54.00±2.61）%]与阴性对照组[（97.33±3.45）%]比较降低,差异有统计学意义（P＜0.05）;流式细胞技术结果显示,红景天苷低、中、高浓度组凋亡细胞比例分别为（20.53±5.76）%、（32.43±3.53）%和（42.40±3.39）%,与阴性对照组[（1.33±0.95）%]相比升高,差异均有统计学意义（P＜0.01）;Hoechst33258核染色法结果显示,红景天苷能够增加凋亡细胞数量;Caspase活性检测结果显示,红景天苷能增强Caspase-3及Caspase-9表达。结论：红景天苷通过增强Caspase-3及Caspase-9表达抑制宫颈癌HeLa细胞增殖,诱导其凋亡,提示红景天苷可能在宫颈癌的治疗中具有一定作用。     

Clusterin confers paclitaxel resistance in cervical cancer

OBJECTIVE: To measure clusterin expression in cervical cancer tissues and cell lines and to evaluate whether clusterin confers resistance to paclitaxel in cervical cancer cells. METHODS: Immunohistochemical staining for clusterin was performed on 15 normal cervical tissues and 32 primary cervical cancer tissues, and clusterin expression in cervical cancer cell lines was quantified by Western blotting. The correlation between clusterin expression level and paclitaxel IC50 in cervical cancer cell lines was evaluated. The effect of clusterin siRNA on paclitaxel resistance was evaluated by XTT assays. RESULTS: Cervical cancer tissues expressed significantly higher levels of clusterin than did normal cervical tissues (4.08 vs. 1.35, P<0.05). Clusterin expression levels were correlated with paclitaxel resistance in cervical cancer cell lines, and transfection of clusterin siRNA into HeLaS3 cells significantly decreased their resistance to paclitaxel (P<0.05). CONCLUSION: Our finding that clusterin expression was significantly higher in cervical cancer than in normal cervical tissues suggests that clusterin may confer paclitaxel resistance in cervical cancer cells.